Biomarkers Journal Open Access

  • ISSN: 2472-1646
  • Journal h-index: 7
  • Journal CiteScore: 1.05
  • Journal Impact Factor: 0.69
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Reach us +32 25889658

Abstract

New Anti Hyperglycemic Drugs on Metabolic Associated Fatty Liver Disease: A Mini Review

Juana Carretero Gómez, José Carlos Arévalo Lorido, Francisco Javier Carrasco-Sánchez, José Pablo Miramontes González and Javier Ena

Non-alcoholic fatty liver disease is a chronic condition characterized by the accumulation of fat in the liver. Steatosis, defined by fat accumulation in more than 5% of hepatocytes, is an active status that can regress or progress to liver cirrhosis. Therefore, an early diagnosis and treatment are critical to prevent an irreversible condition. Metabolic-associated fatty liver disease has been proposed as a more appropriate term to describe the liver disease associated with metabolic dysfunction. There is a gap in pharmacotherapy for earlier stages of non-alcoholic fatty liver disease. These new diagnostic criteria will encourage the initiation of drugs that promote weight loss early to prevent irreversible damage. The European Association for the Study of the Liver have been proposed different models that combine clinical and biochemical parameters to improve both, the diagnosis and early approach. Weight loss is the more straightforward strategy to improve prognosis. It is necessary to achieve a 7%-10% weight loss to improve most of the histopathological features, including fibrosis. The new antihyperglycemic drugs glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors may improve liver histology and clinical outcomes, mainly through weight loss and improved insulin resistance.